Clinical trials: Dendritic Cell
Carcinoma, Renal Cell
Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney Cancer
The primary purpose of this study is to determine the safety of injections prepared from donor blood cells fused to a patient's own tumor cells which are then used to treat advanced (Stage IV) kidney cancer (renal cell carcinoma…
- Trial name
- NCT00050323
- Testing
- Allogeneic DCs and Autologous RCC Tumor Derived Cells
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Genzyme, a Sanofi Company
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer
This clinical trial studies massage therapy given by caregiver in treating quality of life of young patients undergoing treatment for cancer.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Angioimmunoblastic T-cell Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
- Trial name
- NCT01053494
- Testing
- massage therapy, questionnaire administration, quality-of-life assessment
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Wake Forest University Health Sciences
Diabetes Mellitus
The Treatment of Patients With Type 1 Diabetes Mellitus With Autologous Tolerogenic Dendritic Cells
The purpose of this study is to determine the safety and tolerability of the administration of tolerogenic dendritic cells in patients with type 1 diabetes mellitus.
- Trial name
- NCT05207995
- Testing
- Autologous tolerogenic dendritic cells, Standard treatment according to the clinical protocols
- Where
- Belarus
- Volunteers
- 32 people
- Sponsor
- Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Colorectal Cancer
Autologous Antigen-activated Dendritic Cells in the Treatment of Patients With Colorectal Cancer
The purpose of this work: to assess the tolerability and effectiveness of the autogemotherapy method on the basis of autologous antigen-activated dendritic cells in the treatment of patients with colorectal cancer.
- Trial name
- NCT03214939
- Testing
- Immunotherapy based on dendritic cells
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Research Institute of Fundamental and Clinical Immunology
Prostate Cancer
Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients' Own Immune Cells.
The purpose of this study is to assess the safety and activity of a type of vaccine as immune therapy for prostate cancer. This vaccine will be made for each participant's own immune cells (called dendritic cells) obtained by…
- Trial name
- NCT00289341
- Testing
- vaccine vehicle only, DC/LNCaP
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Rockefeller University
Melanoma
Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma
The purpose of this study is to determine if treatment with the autologous cellular vaccine, Melaxin, in combination with Bacillus Calmette-Guerin (BCG) injections is effective in Stage IV malignant melanoma.
- Trial name
- NCT00671554
- Testing
- Melaxin (autologous dendritoma vaccine) and BCG
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Prisma Health-Upstate
Cutaneous Melanoma, Melanoma
A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma
This phase II trial studies the effect of a vaccine called CDX-1401 given with or without a biologic drug called CDX-301 in treating patients with stage IIB-IV melanoma.
- Conditions
- Cutaneous Melanoma, Melanoma, Melanoma of Unknown Primary, Mucosal Melanoma
- Trial name
- NCT02129075
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Recombinant Flt3 Ligand
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients
Objectives: This is an exploratory study, consisting of two parts. In part I dose escalation is performed and the primary objective is the safety of different doses of TLR-DC and Trimix DC.
- Trial name
- NCT01530698
- Testing
- autologous dendritic cell vaccine
- Where
- Netherlands
- Volunteers
- 28 people
- Sponsor
- Radboud University Medical Center
Kidney Cancer
Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer
RATIONALE: Tretinoin may help cells that are involved in the body's immune response to work better. Interleukin-2 may stimulate the white blood cells to kill kidney cancer cells.
- Trial name
- NCT00100906
- Testing
- IL-2, ATRA
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
de Novo Glioblastoma
A Phase I Study of Immunotherapy With GSC -Loaded Dendritic Cells in Patients With Recurrent Glioblastoma
Mono-center, un-controlled, open label, first in human, clinical trial. Approximately 20 patients (in order to achieve 12 valuable patients). The expected accrual time would range between 12 and 18 months.
- Trial name
- DENDR-STEM (NCT02820584)
- Testing
- GSC-loaded autologous dendritic cells
- Volunteers
- 20 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Glioblastoma, Glioblastoma Multiforme
Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma
The purpose of this study is to test the safety and effects of a special type of a cancer vaccine called a 'dendritic cell vaccine' in patients with either newly diagnosed or recurrent glioblastoma.
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioma, Astrocytoma
- Trial name
- NCT02010606
- Testing
- Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy, Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Cedars-Sinai Medical Center
Kidney Cancer, Melanoma (Skin)
Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer
RATIONALE: Gene-modified lymphocytes may stimulate the immune system in different ways and stop tumor cells from growing. High-dose aldesleukin may stimulate lymphocytes to kill tumor cells.
- Conditions
- Kidney Cancer, Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00704938
- Testing
- aldesleukin, anti-p53 T-cell receptor-transduced peripheral blood lymphocytes, autologous dendritic cell-adenovirus p53 vaccine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma
Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma
Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy with or without peripheral stem cell transplantation in treating patients who have recurrent or refractory lymphoma.
- Conditions
- AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma, Post-transplant Lymphoproliferative Disorder, Recurrent Childhood Large Cell Lymphoma
- Trial name
- NCT00036855
- Testing
- rituximab, indium In 111 ibritumomab tiuxetan, yttrium Y 90 ibritumomab tiuxetan
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Primary Mediastinal B-cell Lymphoma, Diffuse, Large B-cell Lymphoma
CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with B cell lymphomas or leukemias that involves taking white blood cells from the patient, growing them…
- Conditions
- Primary Mediastinal B-cell Lymphoma, Diffuse, Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma, Mantle Cell
- Trial name
- NCT00924326
- Testing
- Fludarabine, Cyclophosphamide, Anti-cluster of differentiation 19 (CD19)-CAR PBL
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Graft Versus Host Disease, Leukemia
Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer
RATIONALE: Umbilical cord blood transplantation may allow doctors to give higher doses of chemotherapy or radiation therapy and kill more cancer cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00003335
- Testing
- anti-thymocyte globulin, busulfan, cyclosporine
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Case Comprehensive Cancer Center
Cancer
Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells.
- Trial name
- NCT00003538
- Testing
- graft versus host disease prophylaxis/therapy, allogeneic bone marrow transplantation
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Advanced Non-small Cell Lung Cancer
AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer
This clinical study is looking at a vaccine called AST-VAC2 in adult patients with advanced non-small cell lung cancer (NSCLC). The main aim of the study: If the dose can be given safely to patients, learn more about the…
- Trial name
- NCT03371485
- Testing
- AST-VAC2
- Where
- 2 sites in United Kingdom
- Volunteers
- 9 people
- Sponsor
- Cancer Research UK
Brain and Central Nervous System Tumors, Lymphoma
Gallium Nitrate in Treating Children With Brain Tumor, Neuroblastoma, Rhabdomyosarcoma, Non-Hodgkin's Lymphoma, or Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: : Phase I trial to study the effectiveness of gallium nitrate in young patients who have malignant…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Sarcoma
- Trial name
- NCT00002543
- Testing
- gallium nitrate
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Medical College of Wisconsin
Acute Myelogenous Leukemia
Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients
This research study is studying a cancer vaccine called Dendritic Cell/AML Fusion vaccine (DC/AML vaccine) as a possible treatment for Acute Myelogenous Leukemia (AML).
- Trial name
- NCT03679650
- Testing
- DC/AML fusion cells
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Beth Israel Deaconess Medical Center
HIV Vaccine
Therapeutic Vaccine Based on aDC1 Dendritic Cells for the Control of Viremia After ATI in HIV Infected Individuals
The goal of this interventional study is to validate the strategy of adjuvant therapy with dendritic cells in HIV infection in chronically infected individuals.
- Trial name
- NCT05786937
- Testing
- Alpha-type-1 Polarizing Dendritic Cells (aDC1) unpulsed with HIV peptides, Alpha-type-1 Polarizing Dendritic Cells (aDC1) pulsed with HIV peptides, Commercial ringer´s lactate solution
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- University of Sao Paulo General Hospital